Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

MDX2001

Bispecific antibody · Immune activation, directed at hepatocyte growth factor receptor (c-Met) (MET), trophoblast cell surface antigen 2 (TROP2) (TACSTD2) and CD3 T-cell surface antigen (CD3E) · developed by ModeX Therapeutics, An OPKO Health Company

Phase 1/2 Most advanced trial
OPK Developer
1 Registered trials

What is MDX2001?

MDX2001 is a tetra-specific antibody that binds CD3 and CD28 on T cells and the tumor-associated antigens c-Met and TROP2 on tumor cells. By cross-linking T cells to tumor cells, it is intended to trigger a cytotoxic T-lymphocyte response against c-Met and TROP2-expressing tumors. It is being studied in multiple solid tumors, including gastrointestinal, lung, breast, renal and prostate cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
hepatocyte growth factor receptor (c-Met) (MET), trophoblast cell surface antigen 2 (TROP2) (TACSTD2), CD3 T-cell surface antigen (CD3E), CD28
Mechanism
Immune activation, directed at hepatocyte growth factor receptor (c-Met) (MET), trophoblast cell surface antigen 2 (TROP2) (TACSTD2) and CD3 T-cell surface antigen (CD3E)
Pathways
T-cell mediated cytotoxicity, tumor cell proliferation, survival and invasion
Therapy area
Oncology
Developer
ModeX Therapeutics, An OPKO Health Company (OPK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06239194 Phase 1/2 Biliary Tract Cancer Recruiting OPK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Biliary Tract CancerBreast CancerCervical CancerColon CancerEndometrial CancerEsophageal CancerGastric CancerGastroEsophageal CancerHead and Neck CancerHepatocellular CancerNon-small Cell Lung CancerPancreatic CancerProstate CancerRectal Cancer

Other drugs acting on MET / TACSTD2 / CD3E / CD28

More from ModeX Therapeutics, An OPKO Health Company

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the OPK page.

Follow OPK, the company behind MDX2001

See OPK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OPK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.